Integrated vascular delivery system

Information

  • Patent Grant
  • 10668252
  • Patent Number
    10,668,252
  • Date Filed
    Thursday, April 12, 2018
    7 years ago
  • Date Issued
    Tuesday, June 2, 2020
    5 years ago
Abstract
An integrated vascular delivery system having a frame configured to receive a catheter insertable in a patient to deliver fluid at an insertion site. The frame includes a first hub, a second hub, and a pair of flexible lateral members extending between the hubs and including a tubular lateral member. The system also includes a fluidic channel that fluidically communicates with the catheter, wherein the fluidic channel passes through the tubular lateral member and at least one of the hubs, and includes a fixed turnabout portion in which fluid flows in a direction different from that within the catheter. The first and second hubs provide anchoring points on the patient distributed around the insertion site and on opposite ends of the catheter, thereby anchoring the frame to the patient and stabilizing the catheter. A method is provided for using an integrated vascular delivery system.
Description
FIELD

The present disclosure relates generally to the medical care field, and more specifically to an improved vascular delivery system in the intravenous therapy field.


BACKGROUND

This section provides background information related to the present disclosure which is not necessarily prior art.


Patients undergoing medical treatment often require a form of intravenous (IV) therapy, in which a fluid is administered to the patient through a vein of the patient. IV therapy is among the fastest ways to deliver fluids and medications into the body of the patient. Intravenously infused fluids, which typically include saline, drugs, blood, and antibiotics, are conventionally introduced to the patient through a flexible catheter positioned at any of several venous routes, such as peripheral veins and central veins.


To set up IV therapy with conventional devices and methods, the caregiver positions the catheter over the selected vein and uses a needle within the catheter to pierce the skin and allow insertion of the catheter into the vein. The catheter is typically positioned such that the distal inserted end of the catheter points toward the midline of the patient (e.g., for a peripheral IV line on the arm, the catheter body is positioned on the forearm and points toward the elbow). The caregiver then withdraws the needle from the catheter, leaving the catheter inserted in the vein. The proximal end of the catheter, relative to the midline of the catheter, is fixed to the end of a catheter hub that is proximal relative to the midline of the patient. The caregiver connects the catheter to a fluid supply through external tubing, including extension tubing that is typically attached to the distal end of the catheter hub relative to the midline of the patient, and that the caregiver typically bends into a U-shape. To avoid unscheduled IV line restarts, the catheter and tubing are typically secured against the skin of the patient with tape or similar catheter stabilization devices (CSDs) such as adhesive stabilizing pads that restrain the catheter body.


However, conventional devices and methods for IV therapy have drawbacks. The extension tubing may catch on nearby obstacles during patient movement or caregiver manipulation, which may cause painful vein irritation and compromise the IV. Tape and other existing CSDs are not optimal for stabilization because securing the round, rigid, and bulky components such as the catheter and tubing against the skin can be difficult and ineffective. Tape and other existing CSDs do not fully prevent the catheter from moving within the vein, which leads to patient-endangering complications including catheter dislodgement, infiltration (fluid entering surrounding tissue instead of the vein), and phlebitis (inflammation of the vein). Adhesive stabilizing pads tend to result in other undesired effects, such as skin irritation and/or breakdown due to prolonged concentrated adhesion to the skin. Furthermore, tape and current CSDs restrain the catheter on only one side of the catheter insertion site, and do not prevent the catheter from painfully and dangerously pivoting around the insertion site and moving within the vein.


Thus, there is a need in the intravenous therapy field to create an improved vascular delivery system that overcomes one or more of the drawbacks of the conventional vascular delivery systems. This invention provides such an improved vascular delivery system.





DRAWINGS

The drawings described herein are for illustrative purposes only of selected embodiments and not all possible implementations, and are not intended to limit the scope of the present disclosure.



FIG. 1 is the integrated vascular delivery system of a preferred embodiment;



FIG. 2 is a semi-transparent overhead view of the integrated vascular delivery system of a preferred embodiment;



FIG. 3 is a semi-transparent view of the integrated vascular delivery system of another preferred embodiment;



FIGS. 4A-4D are semi-transparent overhead views of variations of the integrated vascular delivery system of another preferred embodiment;



FIGS. 5A-5F are schematics of a method for using the integrated vascular delivery system of a preferred embodiment; and



FIGS. 6A-6C are overhead, side, and perspective views, respectively, of a variation of the step of folding in a method for using the integrated vascular delivery system of a preferred embodiment.





Corresponding reference numerals indicate corresponding parts throughout the several views of the drawings.


DETAILED DESCRIPTION

The following description of preferred embodiments of the present teachings is not intended to limit the disclosure to these preferred embodiments, but rather to enable any person skilled in the art to make and use this invention.


1. Integrated Vascular Delivery System


As shown in FIGS. 1 and 2, the integrated vascular delivery system 100 of the preferred embodiments includes: a frame 110 configured to receive a catheter 170 insertable in a patient to deliver fluid at an insertion site, in which the frame includes a first hub 120, a second hub 130, and a pair of flexible lateral members 140 extending between the hubs and including a tubular lateral member 140′; and a fluidic channel 150 that fluidically communicates with the catheter, wherein the fluidic channel 150 passes through the tubular lateral member 140′ and at least one of the hubs, and includes a fixed turnabout portion 156 in which fluid flows in a direction different from that within the catheter 170. The first and second hubs preferably provide first and second anchoring points 122 and 132, respectively, on the patient such that the anchoring points are distributed around the insertion site 112 and on opposite ends of the catheter, thereby anchoring the frame to the patient and stabilizing the catheter 170. Fluid flow in the turnabout portion 156 of the fluidic channel 150 is preferably opposite of that within the catheter, and the turnabout portion is preferably fixed in such a way as to reduce the likelihood of snagging or catching on nearby objects. In one preferred embodiment, the system includes a second tubular lateral member 140′ and a second fluidic channel 150 that fluidically communicates with the catheter 170 and passes through the second tubular lateral member 140′. In a preferred embodiment, the frame 110 is configured to receive the catheter as an integral part of the system, in which the catheter 170 is embedded in a portion of the frame, and more preferably in one of the hubs. However, in an alternative embodiment the frame 110 is configured to receive a separate catheter, which may snap fit into the frame.


In some versions of the system, the system further includes at least one extension tube 180 and/or a fluid supply adapter 182 that delivers fluid from a fluid supply to the fluidic channel. The system functions to enable access to the vein of a patient undergoing intravenous (IV) therapy with an included catheter, administer fluids intravenously through the catheter, and securely and safely stabilize the catheter on the patient. The system is preferably used to administer drugs, antibiotics, saline, or blood, but may be used to administer any suitable fluid to a patient. The system is preferably used to create, stabilize, and maintain an IV line on a peripheral vein such as on the arm, hand, or leg, but may alternatively be used for central or peripheral venous access on the neck, chest, or abdomen, or any suitable intravenous intra-arterial location. The system may further be used to create, stabilize, and maintain any suitable catheter- based access to a patient, such as for the transfer of cerebrospinal fluid.


In a preferred embodiment, the catheter 170, frame 110, fluidic channel 150, extension tubing 180, and/or fluid supply adapter 182 are pre-assembled during manufacture of the system to provide an integrated system that is cost-efficient, reduces IV setup time, and packaging waste. The system preferably stabilizes the catheter 170 on the patient with anchoring points distributed around the insertion site 112, more preferably on at least two opposing sides of the insertion site 112, which may reduce or eliminate painful and dangerous pivoting motions of the catheter 170 that may occur during normal patient movement and/or caregiver manipulations. The system is preferably streamlined by aligning the catheter with the fluid supply adapter and reducing external free tubing, which reduces the likelihood of the system catching or snagging on nearby obstacles. The system is preferably a closed system that reduces possible points of contamination and fluid leakage, which improves safety for both the patient and the caregiver. The system is preferably compatible with existing conventional catheter insertion and IV setup procedures, which enables a caregiver to easily use the system without significant additional training.


The frame 110 of the integrated vascular delivery system functions to stabilize the system on the patient. As shown in FIGS. 1 and 2, the frame 110 preferably includes a first hub 120 on one end of the frame that provides a first anchoring point 122 on the patient, a second hub 130 on an end of the frame approximately opposite to the first hub that provides a second anchoring point 132 on the patient, and two flexible lateral members 140 that extend between and flexibly connect the first hub and the second hub, such that the first hub and the second hub move relative to one another with a significant number of degrees of freedom. In particular, the lateral members 140 preferably are reversibly bendable to fold one of the first and second hubs over the other hub. As shown in FIG. 2, in a preferred embodiment, the lateral members are substantially parallel such that the frame 110 forms an approximately rectangular perimeter 114 around the catheter 170 and insertion site 112. In variations of the frame 110, the frame may include any suitable number of hubs and any suitable number of lateral members, such that the frame forms a perimeter 114 of any suitable shape and size around the insertion site 112. The frame 110 preferably allows visualization of the insertion site 112 of the catheter, such as by leaving an open uncovered area around the catheter, although alternatively the system may include a cover that is transparent, translucent, opaque, or any suitable kind of material, that extends over the frame to cover the insertion site 112 and/or catheter 170. As shown in FIG. 5E, the frame is preferably secured to the patient by securing the first hub 120 and second hub 130 to the patient at the first and second anchoring points, respectively, on opposite sides of the insertion site 112 (preferably distal and proximal to the insertion site) and opposite ends of the catheter 170, thereby stabilizing the catheter. However, the frame 110 may additionally and/or alternatively be secured by securing only the first hub, only the second hub, the lateral members and/or or any other suitable portion of the frame. The frame may alternatively stabilize the catheter at anchoring points located at any suitable locations relative to the catheter insertion site 112. The frame 110, when secured to the patient, enables the integrated vascular system to stabilize the catheter more effectively than conventional catheter securement devices that stabilize the catheter on only one side of the insertion site 112, because stabilizing the catheter on two opposite sides of the insertion site reduces pivoting motions of the catheter that may occur during normal patient movement and/or caregiver manipulations.


The first hub 120 of the frame 110 functions to provide a first anchoring point 122 for the frame. As shown in FIG. 2, in a preferred embodiment, the first hub 120 further functions to house a portion of the fluidic channel 150 within the first hub. The first hub 120 is preferably located on the proximal end of the frame relative to the midline of the patient, such that the first hub provides a first anchoring point 122 proximal to the catheter insertion site relative to the midline of the patient. Alternatively, the first hub 120 may be located on any suitable part of the frame relative to the insertion site 112 to provide a first anchoring point 122 at any suitable location relative to the insertion site 112. As shown in FIG. 5E, the first hub 120 is preferably secured to the skin of the patient with tape, but may additionally and/or alternatively be secured with an adhesive located on the underside of the first hub 120; elastic straps; straps fastened with fasteners such as hooks, hook and loop, or magnets; or any suitable securement mechanism. The first hub may alternatively not be secured to the skin of the patient. In one specific embodiment, the first hub preferably has a relatively wide and thin profile, with a width of approximately 20-30 mm and a thickness of approximately 5 mm. However, the first hub may alternatively be any suitable shape and size. A large width is advantageous for distributing forces over a greater area on the skin, which decreases the chances of the patient developing skin irritations, sores, and other degradations. The thin profile, which is approximately half as thick as conventional vascular access devices, decreases the risk of the hub catching or snagging on bed equipment or other nearby obstacles that could cause the catheter to move within the vein and cause complications such as catheter dislodgement, infiltration, and phlebitis. As shown in FIG. 1, the first hub 120 preferably has rounded edges and preferably has an upper surface that is slightly arched along its lateral axis. The arched upper surface may adapt the first hub to receive tape along the arch for securement to the patient. The first hub may additionally have features that conform to the body of the patient, such as an underside concavity to conform to a limb, finger, or knuckle.


The first hub 120 is preferably made of a rigid or semi-rigid material, such as nylon or silicone, to provide structural support to the frame 110 for stabilizing the system. However, the first hub may alternatively be made of any polymer, metal, composite, or other suitable material. The first hub may be transparent or semi- transparent to allow visualization of the fluid channel 150. The first hub is preferably manufactured through injection molding, but may alternatively be manufactured through stereolithography, casting, milling, or any other suitable manufacturing process known to one skilled in the art.


The first hub 120 and/or the second hub 130 may include a sensor 116 that measures a biometric parameter such as temperature, blood pressure, or pulse rate of the patient. The sensor 116 may additionally and/or alternatively sense any suitable parameter such one pertaining to the fluid, such as pH or flow rate.


The portion of the fluidic channel 150 fixed to the first hub 120 may be coupled to an extension tube and/or fluid supply adapter that function to deliver fluid from a fluid supply to the fluidic channel 150 of the system. The fluid supply adapter preferably includes a connector that attaches the extension tube to a fluid supply, which is preferably a pole-mounted IV bag that supplies fluid through tubing, but may alternatively be a syringe, pump, or other suitable fluid supply. As shown in FIG. 4, the connector is preferably a standard female luer lock connector or Y-connector that commonly interfaces with conventional IV bags, as known to one skilled in the art. Alternatively, the connector may be any suitable male or female connector that is adapted to interface with a fluid supply. The extension tube further functions to provide stress relief if the system is jostled and is preferably made of flexible tubing, such as polymer tubing, but may be a passageway made of any other suitable material. Flexible tubing is advantageous for relieving mechanical stress and reducing chances of patient injury if the system is suddenly disturbed, such as during patient movement or caregiver manipulations. The extension tube is preferably long enough to provide stress relief if needed, but short enough to reduce the chances of the extension tube catching or snagging on nearby obstacles. The length of the extension tube may alternatively be any suitable length, and may depend on the specific application of the system. Other dimensions of the fluid passageway, such as outer diameter and inner diameter, may depend on the specific application of the system.


In alternative versions of the system, the system may include more than one extension tube and/or connector, to facilitate delivering fluid from multiple fluid supplies simultaneously to the system. For example, in an embodiment of the system that includes two fluidic channels 150, the system may include a first extension tube that delivers a first fluid to a first fluidic channel, and a second extension tube that delivers a second fluid to the second fluidic channel. However, two extension tubes may be useful in applications involving the administering of two separate fluids through the same fluidic channel and catheter.


The second hub 130 of the system is preferably similar to the first hub 120, except as noted below. The second hub 130 functions to provide a second anchoring point 132 for the frame 110, preferably on a distal end of the frame relative to the midline of the patient. The second hub is preferably secured distal to the catheter insertion site 112 relative to the midline of the patient, and in one specific embodiment, approximately 15 mm or less distal to the insertion site. However, the second hub may alternatively be secured in any suitable location relative to the insertion site 112. As shown in FIG. 2, the second hub 130 preferably includes a self-sealing septum 134. The self-sealing septum of the second hub functions to provide an opening for an insertion needle to be inserted into the catheter 170 prior to catheter insertion, and to seal the internal channel second hub after withdrawal of the insertion needle within the catheter after catheter insertion, to prevent escape or leakage of blood and other potential biohazards or other fluids. As shown in FIG. 2, the septum 134 is preferably located on the distal side of the second hub 130 relative to the midline of the patient, and is approximately concentric with the catheter 170. The septum is preferably made of a flexible material that self-seals to form a hermetic seal. This self-sealing septum prevents fluid from passing through the distal side of the second hub relative to the midline of the patient, contributing to a closed system in which blood and other fluids will not exit the integrated vascular delivery device after the needle punctures the patient. The septum 134 may alternatively be sealed with a plug, such as a stopper or sealant material applied to the septum.


The second hub 130 may additionally include a reservoir between the septum 134 and the catheter 170. This reservoir may serve as a flash chamber to contain any blood leakage during withdrawal of the insertion needle from the catheter after catheter insertion, or may serve any other suitable purpose.


The second hub 130 may additionally include features at the connection between the second hub 130 and the lateral members that reduce creasing, collapsing, fracture, or other damage in the lateral members when the lateral members are folded to pass one of the hubs over the other hub during insertion of the catheter into the patient. As an example, the second hub may include rounded edges that are contoured to the natural bend radius of the lateral members, to prevent the lateral members from bending too sharply or bending against a sharp edge. As another example, the second hub may include relief cutouts and/or other reinforcements that encourage the lateral members to bend to their natural bend radius.


The lateral members 140 of the frame 110 function to provide structural stability to the frame by stabilizing the first hub 120 relative to the second hub 130. As shown in FIGS. 1 and 2, the frame 110 preferably includes two flexible lateral members, including at least one tubular lateral member 140′. However, in alternative versions of the frame, the frame may include fewer or more lateral members. The lateral members preferably provide structural stability to the frame, and the tubular lateral member 140′ or members preferably house a portion of the fluidic channel 150. The lateral members are preferably parallel with one another and preferably extend between the first and second hubs, to form a perimeter 114 around the catheter 170. However, the lateral members may be in any crossed, non-parallel or any suitable orientation. The lateral members preferably allow the first hub and the second hub to move relative to one another with a significant number of degrees of freedom, including displacement in the compression direction (and subsequent displacement in the tension direction) along the axis of the catheter, displacement in both directions along the other two axes, twisting in both directions along the axis of the catheter, and bending in both directions along the other two axes. In particular, the lateral members are preferably reversibly bendable to fold one of the first and second hubs over the other hub. As shown in FIGS. 5B and 6, during insertion of the catheter into the patient, the lateral members are preferably folded to fold the first hub 120 over the second hub 130, which opens the perimeter 114 around the catheter and exposes the penetrating distal tip of the catheter. The length of the lateral members is preferably approximately 30%-50% longer than the catheter, but may alternatively be shorter or longer depending on the specific application. At least one lateral member 140 may include markings, such as markings similar to those on a ruler, to indicate the depth to which the catheter is inserted into the patient. The lateral members are preferably made of an extruded flexible polymer cut to length and molded to one or both hubs, but may alternatively be made through any suitable manufacturing process and/or out of any suitable material.


In a first preferred embodiment, the pair of lateral members includes a tubular lateral member 140′ and a solid lateral member 140″. The tubular lateral member is preferably a generally straight, soft, and flexible hollow channel such as medical tubing, but may alternatively be any suitable structure with an internal fluid passageway that houses a portion of the fluidic channel 150. The tubular lateral member is preferably rigid enough to provide structural support to the frame 110, but flexible enough to bend and fold across its length without damage during insertion of the catheter. The tubular lateral member may include additional features that enhance the ability to bend without damage. As an example, the tubular lateral member may be tapered along its length and include a thicker wall and/or larger outer diameter near the bending stress point at the second hub 130. As another example, the tubular lateral member may have an elliptical cross-section that is more resistant to bending damage. As another example, at least a portion of the first lateral member may include extendable and foldable pleats, similar to an accordion, that allow curvature of the lateral member with less bending stress.


As shown in FIG. 2, in the first preferred embodiment, the solid lateral member is preferably similar in shape and size to the first lateral member so that the frame 110 is structurally symmetrical, but preferably is a “dummy” structure in that it does not house a portion of the fluidic channel 150. The solid lateral member 140″ preferably is approximately identical in flexibility and strength as the tubular lateral member 140′. However, the solid lateral member 140″ may alternatively have a different shape (e.g., larger diameter or larger thickness) to further enhance stabilization of the first hub 120 relative to the second hub. Similar to the tubular lateral member 140′, the solid lateral member 140″ may additionally include features that enhance the ability to bend without damage.


As shown in FIG. 3, in a second preferred embodiment, the pair of lateral members includes two tubular lateral members 140′, similar to the tubular lateral member of the first preferred embodiment. In this embodiment, the tubular lateral members 140′ are preferably identical and house two separate fluidic channels that direct a first and a second fluid flow between the hubs. However, the tubular lateral members may alternatively be different for serving different purposes. For example, two tubular lateral members 140′ may house two separate fluidic channels that are adapted to carry different types of fluids (e.g., different densities), and the tubular lateral members may have different wall thicknesses to compensate for the different fluids and achieve structural symmetry in the frame. As another example, the tubular lateral members may have different sized lumens.


In some alternative versions, the frame 110 may include fewer or more than two lateral members, in any suitable combination and permutation of tubular and solid lateral members. All of the lateral members may be solid, tubular, or hollow, or any combination thereof In some alternative versions, the lateral members may merge and/or branch upstream and/or downstream. For example, in one alternative embodiment the lateral members may include portions of a thin, flexible sheet that are merged proximal and distal to the insertion site, such that the catheter tip passes through a slot-like opening between the merged portions.


The fluidic channel 150 of the system functions to deliver fluid from a fluid supply to the catheter, and in some embodiments, deliver fluid to and from the catheter. The fluidic channel 150 may additionally and/or alternatively deliver fluid from the catheter 170, such as transferring fluid removed from the patient through the catheter to an external reservoir. As shown in FIG. 2, the fluidic channel 150 preferably includes at least one portion that is fixed within at least one of the hubs and/or within a tubular lateral member 140′. More preferably, the fluidic channel 150 includes a first portion 152 fixed within the first hub 120, a second portion 154 passing through a tubular lateral member 140′, and a turnabout portion 156 fixed within the second hub 130. In a first variation, the fluidic channel 150 may be a continuous length such as a single piece of tubing fixed in the first hub, passing through or serving as the tubular lateral member 140′, fixed in the second hub 130 and fluidically coupled to the catheter. In a second variation, the fluidic channel 150 includes separate lengths such as separate tubing segments joined at various points such as through heat sealing, other plastic welding methods, or fluidic couplings. In a third variation, the fluidic channel 150 includes tubular cavities within one or both hubs, to which a tubular segment joins through a process similar to the second variation. In the third variation, the tubular cavities in the first and/or second hub may be formed by molding, drilling, laser cutting, or in any suitable manufacturing process. In a fourth variation, the fluidic channel 150 may be external to one or more of the hubs and lateral members, such that at least a portion of the fluidic channel is mounted to and passes over the exterior of a hub or lateral member. Other variations of the fluidic channel include every combination and permutation of these variations.


As shown in FIG. 2, the first portion 152 of the fluidic channel 150 preferably includes an inlet located at the midline of the proximal side of the first hub and an outlet located on the distal side of the first hub, relative to the midline of the patient. However, the inlet and outlet of the internal channel may be located on any suitable position on the first hub. The inlet of the first portion of the fluidic channel 150 preferably receives fluid from the extension tubing 180, and the outlet of the internal channel preferably delivers the fluid to at least one of the lateral members of the frame 110, but fluid may alternatively flow in reverse order. The first portion of the fluidic channel 150 preferably includes right angles to direct fluid from the midline of the first hub to a tubular lateral member 140′ located on the side of the frame. However, the first portion of the fluidic channel may alternatively be curved (shown in FIGS. 3 and 4), curvilinear, or any suitable shape for fluid flow through the first hub 120 to the lateral member. The first portion of the fluidic channel may be connected to the extension tube by inserting the extension tube into a hollow recess aligned with the fluidic channel in the first hub and sealing the recess edge with epoxy, but the first hub may alternatively be coupled to the extension tube by press fitting the extension tube into the recess in the first hub, sealing a butt joint with epoxy, or any suitable coupling process.


As shown in FIG. 2, the second portion 154 of the fluidic channel 150 preferably passes through a tubular lateral segment, between the first portion in the first hub 120 and the turnabout portion in the second hub 130.


As shown in FIG. 2, the turnabout portion 156 of the fluidic channel 150 is preferably fixed in such a way to direct fluid flow in a direction different from fluid flow within the catheter 170. The turnabout portion preferably directs fluid flow to a direction opposite of that within the catheter, or in an approximately 180-degree turn. The turnabout portion 156 may include right angles, an elliptical, or a circular turn. The turnabout portion of the fluidic channel is preferably fixed or embedded within the second hub 130 (distal relative to the midline of the patient). Since the catheter is typically inserted in the patient such that its penetrating end points proximally towards the heart of the patient, the approximate 180-degree turn of fluid flow within the internal channel allows the extension tubing to lie proximal to the insertion site 112 relative to the midline of the patient. This position of the fluid supply channel advantageously allows a stand supporting the IV bag or other fluid supply to be kept near the head of a bed or otherwise proximal to the insertion site relative to the midline of the patient, as is typically desired and practiced in patient treatment settings. The internalized fluid flow turn in the turnabout portion of the fluidic channel 150 also is advantageous because it reduces external features that can get caught or snagged on nearby obstacles and disturb the IV setup. Another effect of the turnabout portion is that if the extension tube and/or additional tubing from a fluid supply is pulled or caught, the turnabout portion may enables the frame to stabilize the catheter more effectively by causing the catheter to be pulled further into the patient. For example, in a common catheter placement where the catheter is placed on the forearm with its distal tip pointing proximally towards the crook of the elbow of the patient, if the extension tubing is accidentally pulled posteriorly towards the patient, the tubing will in turn pull the turnabout portion of the fluidic channel and the distal second hub 130 in a posterior direction, thereby pulling the catheter tip proximally and further into the blood vessel of the patient.


In another preferred embodiment, as shown in FIGS. 3-4, the system includes a second fluidic channel 150 that is preferably similar to the first fluidic channel 150, but may alternatively be any of the variations of the first fluidic channel. The second fluidic channel preferably passes through a second tubular lateral member 140′. The second fluidic channel preferably receives a second fluid, which may be the same or different from the first fluid supplied to the first fluidic channel. In this embodiment, as shown in FIGS. 4A-4C, the system may further include a second extension tube 180 that supplies a second fluid to the second fluidic channel. However, as shown in FIG. 4D, the system may include only one extension tube that supplies fluid to one or both fluidic channels. The fluidic channels may have separate inlets on the first hub or may share the same inlet on the first hub in which flow may be regulated with valves or other fluid control means. In one variation, the first and second fluidic channels preferably fluidically communicate with the same catheter in the second hub 130, coupled to the catheter at the same (FIG. 4D) or different points (FIG. 4D) along the length of the catheter. In this variation, the system preferably includes a flow control system 160 that selectively restricts flow of one or both of the fluids to the catheter and therefore to the patient. The flow control system may include one or more valves 162, such as at the extension tubes (FIGS. 4A-4B), at the junction with the catheter 170 (FIGS. 4C-4D), or any suitable location. The flow control system 162 may additionally and/or alternatively use pressure drops, vents, or any suitable technique for controlling fluid flow among the fluidic channels and catheter. The flow control system 162 may also be present in an embodiment that includes only one fluidic channel. In another variation, the first and second fluidic channels preferably fluidically communicate with a catheter with dual lumens, such that one catheter lumen is coupled to the first fluidic channel and another catheter lumen is coupled to a second fluidic channel. In yet another variation, the first and second fluidic channels fluidically communicate with separate catheters. Additional variations expand on these variations with three or more fluidic channels.


Furthermore, the first hub 120 and/or second hub 130 may include multiple internal channels that merge downstream, such that the number of inlets is greater than the number of outlets in the hub. In some variations, one of the hubs may include one or more internal channels that branch downstream, such that the number of inlets is less than the number of outlets. One of the hubs may include one or more internal channels that both branch and merge within the first hub. Multiple internal channels may deliver fluid to multiple catheters or multiple lumens of a catheter.


In some embodiments, the system further includes a catheter 170 having a proximal portion embedded in a portion of the frame, and more preferably in the first or second hub 130. The catheter 170 of the integrated vascular system functions to administer fluids for IV therapy to the patient. The catheter 170 is preferably a conduit insertable into a blood vessel of the patient, but may be any suitable type of catheter. As shown in FIGS. 1-4, the catheter is preferably fluidly connected to the turnabout portion of the fluidic channel and located at the midline of the proximal side of the second hub 130 relative to the midline of the patient. The catheter 170 is preferably aligned with the extension tubing, which reduces and streamlines extraneous external tubing and other connections that may get caught or snagged on nearby obstacles, which is painful and dangerous for the patient. However, the catheter may be positioned at any suitable location on the second hub. In some embodiments, the catheter may be positioned such as having its proximal end fluidically connected to the first, more proximal hub and pointing towards and such that the system lacks a turnabout portion of the fluidic channel. For example, the catheter may be fluidic connected to the first hub that is more proximal to the patient, The catheter is preferably made of a soft, flexible polymer but may be made out of any suitable material. Dimensions of the catheter, including length, diameter, and cannula size, will depend on the specific application. Catheters are known and used in the art, such as that described in U.S. Pat. No. 5,358,493 entitled “Vascular access catheter and methods for manufacture thereof”, which is incorporated in its entirety by this reference. The catheter may include markings, such as those similar to a ruler, along its length to indicate the depth to which the catheter is inserted into the patient.


2. Method of Using an Integrated Vascular Delivery System


As shown in FIGS. 5A-5F, the method 200 of an integrated vascular delivery system preferably includes the steps of: supplying a frame forming a perimeter S210, wherein the frame is configured to receive a catheter having a distal end contained within the perimeter and includes a first hub, a second hub, and a fluidic channel; folding the frame to modify the perimeter of the frame S220, thereby freeing the distal end of the catheter from the perimeter of the frame; inserting the catheter into the patient at an insertion site S230; unfolding the frame to restore the perimeter of the frame around the distal end of the catheter and insertion site S240; securing the frame to the patient at a plurality of anchoring points distributed around the insertion site S250, thereby stabilizing the catheter relative to the insertion site; and allowing fluid to flow between the catheter and the patient S260. The method 200 may be performed to obtain access to the blood vessel of a patient, such as one undergoing intravenous (IV) therapy. The method may be used to administer drugs, antibiotics, saline, blood, or any suitable fluid to a patient, and/or to remove fluid from the patient. The method may be used to create, stabilize, and maintain an IV line at an insertion site on a peripheral vein or artery such as on the arm, hand, or leg, or for central venous access on the neck, chest, or abdomen, or any suitable IV location. Furthermore, the method may be used to create, stabilize, and maintain any suitable catheter-based access to a patient, such as catheters for transfer of cerebrospinal fluid.


As shown in FIG. 5A, the step of supplying a frame S210 preferably includes supplying an integrated vascular delivery system such as that described above. However, the integrated vascular delivery system may alternatively be any suitable system with a frame, first hub and second hub, and a fluidic channel in which the frame can be folded to pass the first hub towards the second hub. For example, a frame forming a perimeter may include a first hub and a second hub coupled with a hinged joint. Furthermore, the integrated vascular delivery system may include fewer or more hubs.


The step of folding a frame S220 functions to expose an insertable end of the catheter and to provide visual clearance for the catheter to be positioned at an insertion site and physical clearance to access the insertion site. As shown in FIGS. 5B and 6A, the step of folding the frame preferably includes passing the first hub of the frame over the second hub of the frame in a first direction. The first hub of the frame is preferably a proximal portion of the frame relative to the patient midline, and the second hub of the frame is preferably a distal portion of the frame relative to the patient midline, but the first hub and second hub may be any suitable portions of the frame. For example, as shown in FIG. 5F, relative to an insertion site at the crook of an elbow of a patient, the first hub is preferably closer to the elbow and the second hub is preferably closer to the hand, such that the step of folding a frame folds the first hub away from the patient, and typically towards a medical caregiver using the system who is standing in front of the patient.


The step of inserting the catheter into the patient at an insertion site S230 includes inserting a needle into a catheter, penetrating the insertion site with the needle, positioning the catheter within the insertion site, and withdrawing the needle from the catheter. The step of inserting the catheter into the patient functions to create a conduit through which fluid can be administered to the patient. In performing the step of penetrating the insertion site with the needle, the needle is preferably pointed proximally relative to the midline of the patient. The step of inserting a needle into a catheter preferably includes inserting a needle through the second hub of the frame, which introduces a piercing tool that is adapted to penetrate the insertion site for catheter insertion. The steps of penetrating the insertion site, positioning the catheter, and withdrawing the needle are known and used by one ordinarily skilled in the art. As shown in FIG. 5C, in a first variation, inserting a needle through the catheter includes passing the needle over the first hub of the frame and through the catheter S232, which maintains the folded orientation of the frame during catheter insertion and to help hold the first hub in place to prevent the first hub from obstructing needle access to the second hub. As shown in FIGS. 6A-6C, in a second variation, inserting a needle through the catheter includes passing the needle under the first hub of the frame and through the catheter S234. In this second variation, the first hub is preferably seated in, or otherwise coupled to an additional mechanism such as a needle housing.


The step of unfolding the frame S240 functions to restore the perimeter of the frame around the distal end of the catheter and insertion site. As shown in FIG. 5D, the step of unfolding the frame preferably includes passing the first hub of the frame over the second hub of the frame in a second direction. The second direction is preferably opposite of the first direction, but may alternatively be any suitable direction and restores the perimeter of the frame around the insertion site. The step of unfolding the frame is facilitated by the step of withdrawing the needle from the catheter, since the needle or other mechanism to which the first hub is coupled is no longer present to hold the first hub in place.


The step of securing the frame to the patient S250 at a plurality of anchoring points around the insertion site functions to stabilize the catheter relative to the insertion site. As shown in FIG. 5E, the step of securing the frame to the patient includes securing the first hub of the frame to the patient at a first anchoring point adjacent to the insertion site, and securing the second hub of the frame to the patient at a second anchoring point opposite the first anchoring point across the insertion site. The plurality of anchoring points preferably include at least two anchoring points approximately opposite to each other, and more preferably include anchoring points distributed approximately equally around the insertion site. In particular, the first anchoring point is preferably distal to the insertion site and the second anchoring point is preferably proximal to the insertion site, relative to the patient. Securing the frame to the patient on two opposite sides of the insertion site functions to effectively reduce or eliminate motions of the catheter within the vein and reduce or eliminate the occurrence of painful and patient-endangering complications including catheter dislodgement, infiltration, and phlebitis. In some variations, the step of securing the frame includes securing any suitable number of hubs at one anchoring point or three or more anchoring points. The first anchoring point is preferably proximal to the insertion site relative to the midline of the patient, and the second anchoring point is preferably distal to the insertion site relative to the midline of the patient, but the first anchoring point and second anchoring point may be at any suitable location relative to the insertion site. Each securing step may include taping the frame to the patient, adhering the frame to the patient with adhesive, strapping the frame to the patient, or any suitable securing mechanism.


The step of allowing the fluid to flow between the catheter and the patient S260 functions to administer fluid to the patient and/or remove fluids from the patient. As shown in FIG. 5F, the step of allowing the fluid to flow preferably includes connecting the fluidic channel to a fluid supply or reservoir. The fluidic channel is preferably connected to the fluid supply or reservoir by fluidly connecting fluidic channel to extension tubing as is well known in the art, but may alternatively be connected to the fluid supply by connecting any suitable portion of the frame through any suitable method. The fluid supply is preferably an IV bag, but may alternatively be any suitable fluid supply. In some variations in which the integrated vascular delivery system includes multiple fluidic channels, the step of allowing the fluid to flow includes connecting a second fluidic channel to a second fluid supply or reservoir.


The method may additionally further include the step of applying a dressing over the insertion site and the frame. The step of applying a dressing functions to protect the insertion site against bacteria, viruses, and other pathogens. The dressing is preferably a breathable, sterile dressing such as Tegaderm, which is known and used to one skilled in the art. As shown in FIG. 5F, the dressing is preferably transparent to allow visualization of the insertion site, and includes adhesive to attach to the skin of the patient and to provide securement of the frame. However, the dressing can include any suitable device or method to assist in the protection of the insertion site.


As a person skilled in the art will recognize from the previous detailed description and from the figures and claims, modifications and changes can be made to the preferred embodiments of the invention without departing from the scope of this invention defined in the following claims.

Claims
  • 1. An integrated vascular delivery system comprising: a first hub having a proximal region, the first hub comprising: a catheter configured for insertion into a patient extending from the proximal region; andat least one fluidic channel configured to communicate with the catheter within the first hub and extending from the proximal region of the first hub;a second hub spaced apart from the first hub and configured to stabilize the system; anda first and a second lateral member extending between the first hub and the second hub, wherein the at least one fluidic channel passes through at least one of the first and second lateral members.
  • 2. The system of claim 1, wherein the lateral member including the fluidic channel extends from a central portion of the first hub to a spaced apart portion of the proximal region.
  • 3. The system of claim 1, wherein the at least one fluidic channel passes through the first hub at an angle such that the at least one fluidic channel extends from a center of the first hub to an outer peripheral portion of the proximal region of the first hub.
  • 4. The system of claim 1, wherein the at least one fluidic channel includes a fixed turnabout portion in which a direction of fluid flow through the at least one fluidic channel is angularly displaced by approximately 180 degrees.
  • 5. The system of claim 1, wherein the first and second lateral members are bendable and configured to allow one of the first and second hubs to fold over the other of the first and second hubs.
  • 6. The system of claim 1, wherein at least one of the first and second lateral members extends through the second hub.
  • 7. The system of claim 1, wherein the first and second lateral members extend through the second hub.
  • 8. The system of claim 1, wherein the at least one fluidic channel comprises a first fluidic channel and a second fluidic channel.
  • 9. The system of claim 8, further comprising a first extension tube defining a first flow path and a second extension tube defining a second flow path, the first extension tube fluidically coupled to the first fluidic channel and the second extension tube fluidically coupled to the second fluidic channel.
  • 10. The system of claim 9, wherein the first extension tube is integrally formed with the first fluidic channel and extends through the second hub and the second extension tube is integrally formed with the second fluidic channel and extends through the second hub.
  • 11. The system of claim 1, further comprising a septum coupled to the first hub, the septum being configured to receive a needle.
  • 12. The system of claim 1, wherein the first hub is configured to be positioned on a first side of an insertion point and the second hub is configured to be positioned on a second side of the insertion point.
  • 13. A method of using an integrated vascular delivery system, the method comprising: supplying an integrated vascular delivery system, wherein the system comprises a first hub having a proximal region, a catheter extending from the proximal region, a second hub, a first and a second lateral member extending between the first hub and the second hub, and at least one fluidic channel that fluidically communicates with the catheter within the first hub, extends from the proximal region of the first hub, and passes through at least one of the first and second lateral members, wherein the system is configured to allow one of the first hub and the second hub to fold over the other of the first and second hubs, thereby exposing a proximal end of the catheter;inserting the catheter into a patient at an insertion site;unfolding the system; andsecuring the system to the patient at a plurality of anchoring points around the insertion site, thereby stabilizing the system relative to the insertion site.
  • 14. The method of claim 13, further comprising allowing fluid to flow between the catheter and the patient.
  • 15. The method of claim 13, further comprising decoupling at least one of the first hub and the second hub from a needle housing.
  • 16. The method of claim 13, wherein the system further comprises a needle extending through the first hub and the catheter, the method further comprising the step of removing the needle from the first hub and the catheter.
  • 17. The method of claim 13, wherein securing the system comprises securing the first hub at a first anchoring point distal to the insertion site and securing the second hub at a second anchoring point proximal to the insertion site.
REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/427,714 filed on Feb. 8, 2017, which is a continuation of U.S. patent application Ser. No. 14/602,735 filed on Jan. 22, 2015 (now U.S. Pat. No. 9,592,366, issued on Mar. 14, 2017), which is a continuation of U.S. patent application Ser. No. 13/930,797 filed on Jun. 28, 2013 (now U.S. Pat. No. 8,968,252, issued on Mar. 3, 2015), which is a continuation of U.S. patent application Ser. No. 13/665,162 filed on Oct. 31, 2012 (now U.S. Pat. No. 8,668,674, issued on Mar. 11, 2014), which is a continuation of U.S. patent application Ser. No. 12/855,013, filed on Aug. 12, 2010 (now U.S. Pat. No. 8,323,249, issued on Dec. 4, 2012), which claims the benefit of U.S. Provisional Application No. 61/233,859, filed on Aug. 14, 2009. The entire disclosure of each of the above applications is incorporated herein by reference.

US Referenced Citations (799)
Number Name Date Kind
2868200 Gewecke Jan 1959 A
3561429 Jewett Feb 1971 A
3729031 Baldwin Apr 1973 A
4013080 Froning Mar 1977 A
4160450 Doherty Jul 1979 A
4316461 Marais et al. Feb 1982 A
4380234 Kamen Apr 1983 A
4397641 Jacobs Aug 1983 A
4424833 Spector et al. Jan 1984 A
4430073 Bemis et al. Feb 1984 A
4432752 Marlon Feb 1984 A
4435173 Siposs et al. Mar 1984 A
4436519 O'Neill Mar 1984 A
4576589 Kraus et al. Mar 1986 A
4591356 Christie May 1986 A
4605011 Näslund Aug 1986 A
4681567 Masters et al. Jul 1987 A
4695274 Fox Sep 1987 A
4755170 Golden Jul 1988 A
4776841 Catalano Oct 1988 A
4798594 Hillstead Jan 1989 A
4799494 Wang Jan 1989 A
4801295 Spencer Jan 1989 A
4834271 Litwin May 1989 A
4834718 McDonald May 1989 A
4846796 Carrell et al. Jul 1989 A
4890626 Wang Jan 1990 A
4898587 Mera Feb 1990 A
4909798 Fleischhacker et al. Mar 1990 A
4935010 Cox et al. Jun 1990 A
4936830 Verlier Jun 1990 A
4941883 Venturini Jul 1990 A
4944725 McDonald Jul 1990 A
4944728 Carrell et al. Jul 1990 A
4952207 Lemieux Aug 1990 A
4964854 Luther Oct 1990 A
4976698 Stokley Dec 1990 A
5000740 Ducharme et al. Mar 1991 A
5049136 Johnson Sep 1991 A
5084023 Lemieux Jan 1992 A
5084026 Shapiro Jan 1992 A
5085648 Purdy et al. Feb 1992 A
5092845 Chang Mar 1992 A
5098048 Chen Mar 1992 A
5116324 Brierley et al. May 1992 A
5129884 Dysarz Jul 1992 A
5135504 McIees Aug 1992 A
5147327 Johnson Sep 1992 A
5147333 Raines Sep 1992 A
5147375 Sullivan et al. Sep 1992 A
5171234 Jepson et al. Dec 1992 A
5192275 Burns Mar 1993 A
5199948 McPhee Apr 1993 A
5201717 Wyatt et al. Apr 1993 A
5207647 Phelps May 1993 A
5211634 Vaillancourt May 1993 A
5215525 Sturman Jun 1993 A
5215528 Purdy et al. Jun 1993 A
5215537 Lynn et al. Jun 1993 A
5232010 Rozenblatt et al. Aug 1993 A
5238010 Grabenkort et al. Aug 1993 A
5254097 Schock et al. Oct 1993 A
5269771 Thomas et al. Dec 1993 A
5295970 Clinton et al. Mar 1994 A
5295977 Cohen et al. Mar 1994 A
5300034 Behnke et al. Apr 1994 A
5312368 Haynes May 1994 A
5314411 Bierman et al. May 1994 A
5351383 Behnke et al. May 1994 A
5330438 Gollobin et al. Jul 1994 A
5352205 Dales et al. Oct 1994 A
5354275 Behnke et al. Oct 1994 A
5354282 Bierman Oct 1994 A
5356390 Erskine Oct 1994 A
5360408 Vaillancourt Nov 1994 A
5364368 Kauffman et al. Nov 1994 A
5368801 Vaillancourt Nov 1994 A
5375589 Bhatta Dec 1994 A
5376071 Henderson Dec 1994 A
5376082 Phelps Dec 1994 A
5400500 Behnke et al. Mar 1995 A
5405331 Behnke et al. Apr 1995 A
5413562 Swauger May 1995 A
5425465 Healy Jun 1995 A
5425721 Malenchek Jun 1995 A
5439451 Collinson et al. Aug 1995 A
5445623 Richmond Aug 1995 A
5456668 Ogle, II Oct 1995 A
5458658 Sircom Oct 1995 A
5462255 Rosen et al. Oct 1995 A
5472430 Vaillancourt et al. Dec 1995 A
5474544 Lynn Dec 1995 A
5476452 Thompson Dec 1995 A
5487728 Vaillancourt Jan 1996 A
5487734 Thorne et al. Jan 1996 A
5498247 Brimhall Mar 1996 A
5501674 Trombley, III et al. Mar 1996 A
5509912 Vaillancourt et al. Apr 1996 A
5514111 Phelps May 1996 A
5514116 Vaillancourt et al. May 1996 A
5522804 Lynn Jun 1996 A
5545146 Ishak Aug 1996 A
5549651 Lynn Aug 1996 A
5558651 Crawford et al. Sep 1996 A
5562631 Bogert Oct 1996 A
5575769 Vaillancourt Nov 1996 A
5575777 Cover et al. Nov 1996 A
5591138 Vaillancourt Jan 1997 A
5601536 Crawford et al. Feb 1997 A
5643216 White Jul 1997 A
5669891 Vaillancourt Sep 1997 A
5676656 Brimhall Oct 1997 A
5676658 Erskine Oct 1997 A
5688253 Paradis Nov 1997 A
5697914 Brimhall Dec 1997 A
5697915 Lynn Dec 1997 A
5702367 Cover et al. Dec 1997 A
5702371 Bierman Dec 1997 A
5704914 Stocking et al. Jan 1998 A
5713876 Bogert et al. Feb 1998 A
5725499 Silverstein et al. Mar 1998 A
5727770 Dennis Mar 1998 A
5735826 Richmond Apr 1998 A
5735827 Adwers et al. Apr 1998 A
5740810 Johnson et al. Apr 1998 A
5743884 Hasson et al. Apr 1998 A
5746727 Graves et al. May 1998 A
5749857 Cuppy May 1998 A
5755709 Cuppy May 1998 A
5769825 Lynn Jun 1998 A
5788675 Mayer Aug 1998 A
5810780 Brimhall Sep 1998 A
5827221 Phelps Oct 1998 A
5830184 Basta Nov 1998 A
5833662 Stevens Nov 1998 A
5846227 Osterlind Dec 1998 A
5879330 Bell Mar 1999 A
5902274 Yamamoto et al. May 1999 A
5911705 Howell Jun 1999 A
5913845 Brimhall Jun 1999 A
5916199 Miles Jun 1999 A
5935110 Brimhall Aug 1999 A
5954698 Pike Sep 1999 A
5957887 Oesterlind et al. Sep 1999 A
5989220 Shaw et al. Nov 1999 A
5997504 Bell Dec 1999 A
6001080 Kuracina et al. Dec 1999 A
6004294 Brimhall et al. Dec 1999 A
6022339 Fowles et al. Feb 2000 A
6027480 Davis et al. Feb 2000 A
6033382 Basta Mar 2000 A
6056718 Funerburk et al. May 2000 A
6077244 Botich et al. Jun 2000 A
6077248 Zumschlinge Jun 2000 A
6086564 McLaughlin Jul 2000 A
6142981 Heck et al. Nov 2000 A
6149632 Landuyt Nov 2000 A
6152913 Feith et al. Nov 2000 A
6162206 Bindokas et al. Dec 2000 A
6168137 Paradis Jan 2001 B1
6171287 Lynn et al. Jan 2001 B1
6197007 Thorne et al. Mar 2001 B1
6210624 Mayer Apr 2001 B1
6213978 Voyten Apr 2001 B1
6221048 Phelps Apr 2001 B1
6228065 Lynn May 2001 B1
6261259 Bell Jul 2001 B1
6261268 Mayer Jul 2001 B1
6273869 Vaillancourt Aug 2001 B1
6273871 Davis et al. Aug 2001 B1
RE37357 Lynn Sep 2001 E
6299602 Miller et al. Oct 2001 B1
6302866 Marggi Oct 2001 B1
6342120 Basta Jan 2002 B1
6375639 Duplessie et al. Apr 2002 B1
6379333 Brimhall et al. Apr 2002 B1
6379337 Mohammad Apr 2002 B1
6443929 Kuracina et al. Sep 2002 B1
6506181 Meng et al. Jan 2003 B2
6520938 Funderburk et al. Feb 2003 B1
6569120 Green et al. May 2003 B1
RE38145 Lynn Jun 2003 E
6572586 Wojcik Jun 2003 B1
6572588 Bierman Jun 2003 B1
6572591 Mayer Jun 2003 B2
6595955 Ferguson et al. Jul 2003 B2
6623461 Wilkinson et al. Sep 2003 B1
6638252 Moulton et al. Oct 2003 B2
6652490 Howell Nov 2003 B2
6663599 Osborne et al. Dec 2003 B2
6673046 Bierman et al. Jan 2004 B2
6692468 Waldenburg Feb 2004 B1
6699221 Vaillancourt Mar 2004 B2
6712790 Prestidge et al. Mar 2004 B1
6719726 Meng et al. Apr 2004 B2
6719727 Brimhall et al. Apr 2004 B2
6730096 Basta May 2004 B2
6740277 Howell et al. May 2004 B2
6749588 Howell et al. Jun 2004 B1
6761706 Vaillancourt Jul 2004 B2
6776775 Mohammad Aug 2004 B1
6805860 Alt Oct 2004 B1
6811545 Vaillancourt Nov 2004 B2
6832994 Niedospial, Jr. et al. Dec 2004 B2
6837875 Bierman Jan 2005 B1
6849051 Sramek et al. Feb 2005 B2
6902546 Ferguson Jun 2005 B2
6905483 Newby et al. Jun 2005 B2
6908459 Harding et al. Jun 2005 B2
6921391 Barker et al. Jul 2005 B1
6926721 Basta Aug 2005 B2
6953448 Moulton et al. Oct 2005 B2
6955659 Carter Oct 2005 B1
6972002 Thorne Dec 2005 B2
6981965 Luther et al. Jan 2006 B2
6981966 Green et al. Jan 2006 B2
6984223 Newby et al. Jan 2006 B2
RE38996 Crawford et al. Feb 2006 E
6997902 Thorne et al. Feb 2006 B2
6997913 Wilkinson Feb 2006 B2
6997917 Niedospial, Jr. et al. Feb 2006 B2
7004934 Vaillancourt Feb 2006 B2
7008406 Mayer Mar 2006 B2
7022111 Duplessie et al. Apr 2006 B2
7033339 Lynn Apr 2006 B1
7060055 Wilkinson et al. Jun 2006 B2
7060060 Simpson et al. Jun 2006 B1
7090660 Roberts et al. Aug 2006 B2
7090661 Morris et al. Aug 2006 B2
7112191 Daga Sep 2006 B2
RE39334 Lynn Oct 2006 E
7125398 Garcia, Jr. Oct 2006 B2
7141040 Lichtenberg Nov 2006 B2
7147622 Gutierrez Dec 2006 B2
7220249 Hwang et al. May 2007 B2
7258680 Mogensen et al. Aug 2007 B2
7344516 Erskine Mar 2008 B2
7347842 Thorne et al. Mar 2008 B2
7351230 Smith et al. Apr 2008 B2
7354422 Riesenberger et al. Apr 2008 B2
7396346 Nakajima Jul 2008 B2
7413562 Ferguson et al. Aug 2008 B2
7435238 Reid Oct 2008 B2
7445611 Osborne et al. Nov 2008 B2
7470261 Lynn Dec 2008 B2
7481797 Mahurkar Jan 2009 B2
7507222 Cindrich et al. Mar 2009 B2
7569033 Greene et al. Aug 2009 B2
7604616 Thoresen et al. Oct 2009 B2
7611499 Woehr et al. Nov 2009 B2
7615033 Leong Nov 2009 B2
7618395 Ferguson Nov 2009 B2
7625360 Woehr et al. Dec 2009 B2
7635357 Mayer Dec 2009 B2
7651481 Raybuck Jan 2010 B2
7654988 Moulton et al. Feb 2010 B2
7658725 Bialecki et al. Feb 2010 B2
7666166 Emmert et al. Feb 2010 B1
7670299 Beckman et al. Mar 2010 B2
7670317 Cindrich et al. Mar 2010 B2
7682339 Fujii Mar 2010 B2
7694403 Moulton Apr 2010 B2
7699814 Lande Apr 2010 B2
7713243 Hillman May 2010 B2
7713250 Harding et al. May 2010 B2
7717882 Harding May 2010 B2
7722569 Söderholm et al. May 2010 B2
7736332 Carlyon et al. Jun 2010 B2
7736337 Diep et al. Jun 2010 B2
7736342 Abriles et al. Jun 2010 B2
7740615 Shaw et al. Jun 2010 B2
7744572 Bierman Jun 2010 B2
7749254 Sobelman et al. Jul 2010 B2
7762993 Perez Jul 2010 B2
7763199 Fangrow, Jr. Jul 2010 B2
7766879 Tan et al. Aug 2010 B2
7766897 Ramsey et al. Aug 2010 B2
7771412 Anderson et al. Aug 2010 B2
7776017 Ponzi et al. Aug 2010 B2
7798991 Insignares Sep 2010 B2
7798994 Brimhall Sep 2010 B2
7799000 Silich Sep 2010 B2
7806869 Nilsson et al. Oct 2010 B2
7833201 Carlyon et al. Nov 2010 B2
7862547 Ferguson et al. Jan 2011 B2
7887515 Bierman Feb 2011 B2
7892216 Fangrow, Jr. Feb 2011 B2
7918828 Lundgaard et al. Apr 2011 B2
7931615 Fangrow, Jr. Apr 2011 B2
7959613 Rhad et al. Jun 2011 B2
7972313 Woehr et al. Jul 2011 B2
8012145 Cawley Sep 2011 B2
8025644 Chong et al. Sep 2011 B2
8042689 Fröjd et al. Oct 2011 B2
8043265 Abe et al. Oct 2011 B2
8048031 Shaw et al. Nov 2011 B2
8062262 Christensen et al. Nov 2011 B2
8066669 Christensen et al. Nov 2011 B2
8066670 Cluff et al. Nov 2011 B2
8066675 Cindrich et al. Nov 2011 B2
8066678 Vaillancourt et al. Nov 2011 B2
8070725 Christensen Dec 2011 B2
8079979 Moorehead Dec 2011 B2
8083728 Rome Dec 2011 B2
8092435 Beling et al. Jan 2012 B2
8105286 Anderson et al. Jan 2012 B2
8105288 Keyser et al. Jan 2012 B2
8122923 Krause et al. Feb 2012 B2
8123738 Vaillancourt Feb 2012 B2
8133202 Marsh Mar 2012 B2
8133206 Greene et al. Mar 2012 B2
8147455 Butts et al. Apr 2012 B2
8147465 Kern Apr 2012 B2
8157770 Elwell et al. Apr 2012 B2
8162882 Rubinstein et al. Apr 2012 B2
8162896 Tan Apr 2012 B2
8162914 Kraushaar et al. Apr 2012 B2
8163237 Crawford et al. Apr 2012 B2
8172803 Morrissey et al. May 2012 B2
8172825 Solomon et al. May 2012 B2
8177745 Brechbuehler et al. May 2012 B2
8177753 Vitullo et al. May 2012 B2
8177754 Barnes May 2012 B2
8177755 Berry et al. May 2012 B2
8177760 Rome et al. May 2012 B2
8177762 Beasley et al. May 2012 B2
8177772 Christensen et al. May 2012 B2
8182448 Emmert et al. May 2012 B2
8197452 Harding et al. Jun 2012 B2
8197466 Yokota et al. Jun 2012 B2
8211070 Woehr et al. Jul 2012 B2
8226612 Nakajima Jul 2012 B2
8251950 Albert et al. Aug 2012 B2
8273056 Kuracina et al. Sep 2012 B2
8277424 Pan Oct 2012 B2
8287518 Kitani et al. Oct 2012 B2
8298195 Peppel Oct 2012 B2
8313459 Kiehne Nov 2012 B2
8313469 Fiser Nov 2012 B2
8323249 White Dec 2012 B2
8337471 Baid Dec 2012 B2
8337483 Harding et al. Dec 2012 B2
8357121 Burkholz Jan 2013 B2
8361408 Lynn Jan 2013 B2
8366676 Harding et al. Feb 2013 B2
8377010 Harding et al. Feb 2013 B2
8377040 Burkholz et al. Feb 2013 B2
8382718 Woehr Feb 2013 B2
8382721 Woehr et al. Feb 2013 B2
8398597 Brimhall Mar 2013 B2
8403905 Yow Mar 2013 B2
8408226 Raines et al. Apr 2013 B2
8409165 Niedospial, Jr. et al. Apr 2013 B2
8419688 Woehr et al. Apr 2013 B2
8430850 Gyrn et al. Apr 2013 B2
8439877 Burkholz May 2013 B2
8439891 Milligan May 2013 B1
8444605 Kuracina et al. May 2013 B2
8460247 Woehr et al. Jun 2013 B2
8465441 Srivatsa et al. Jun 2013 B2
8511352 Krause et al. Aug 2013 B2
8529524 Newton et al. Sep 2013 B2
8545454 Kuracina et al. Oct 2013 B2
8556855 Zivkovic et al. Oct 2013 B2
8568372 Woehr et al. Oct 2013 B2
8591469 Keyser et al. Nov 2013 B2
8622967 Davis et al. Jan 2014 B2
8628497 Finnestad et al. Jan 2014 B2
8636697 Scheurer et al. Jan 2014 B2
8647301 Bialecki et al. Feb 2014 B2
8652104 Goral et al. Feb 2014 B2
8657788 Fangrow, Jr. Feb 2014 B2
8657790 Tal et al. Feb 2014 B2
8663169 Emmert et al. Mar 2014 B2
8668674 White et al. Mar 2014 B2
8671964 Py Mar 2014 B2
8684994 Lev et al. Apr 2014 B2
8702675 Imai Apr 2014 B2
8715222 Truitt et al. May 2014 B2
8715250 Tremblay May 2014 B2
8721627 Alpert May 2014 B2
8728035 Warring et al. May 2014 B2
8771230 White et al. Jul 2014 B2
8784387 Woehr Jul 2014 B2
8790310 White et al. Jul 2014 B2
8801678 Panian et al. Aug 2014 B2
8814833 Farrell et al. Aug 2014 B2
8827965 Woehr et al. Sep 2014 B2
8834422 Walker et al. Sep 2014 B2
8834432 Winsor et al. Sep 2014 B2
8840577 Zollinger et al. Sep 2014 B1
8858503 Burkholz et al. Oct 2014 B2
8870835 Baid Oct 2014 B2
8870846 Davis et al. Oct 2014 B2
8876784 Coete, Sr. et al. Nov 2014 B2
8882742 Dikeman et al. Nov 2014 B2
8900192 Anderson et al. Dec 2014 B2
8900199 Kawai et al. Dec 2014 B2
8910919 Bonnal et al. Dec 2014 B2
8915891 Bornhoft Dec 2014 B2
8932259 Stout et al. Jan 2015 B2
8951233 Mansour Feb 2015 B2
8956328 Antonucci Feb 2015 B2
8956330 Fangrow, Jr. Feb 2015 B2
8968252 White et al. Mar 2015 B2
8968261 Kimball et al. Mar 2015 B2
8968271 Guala Mar 2015 B2
8974425 Tachizaki et al. Mar 2015 B2
8979804 Ho et al. Mar 2015 B2
8986227 Belson Mar 2015 B2
8998851 Constantineau et al. Apr 2015 B2
9011382 Nilsson et al. Apr 2015 B2
9017288 Starnes Apr 2015 B1
9017295 Pan Apr 2015 B2
9032997 Abura et al. May 2015 B2
9033927 Maan et al. May 2015 B2
9033952 Chen May 2015 B2
9039047 Imai May 2015 B2
9044552 Schraga Jun 2015 B2
9044585 Masuda et al. Jun 2015 B2
9050128 Ros Jun 2015 B2
9056188 Hager et al. Jun 2015 B2
9067049 Panian et al. Jun 2015 B2
9089680 Ueda et al. Jul 2015 B2
9089681 Ueda et al. Jul 2015 B2
9089682 Yeh et al. Jul 2015 B2
9095679 Nishimura et al. Aug 2015 B2
9095683 Hall et al. Aug 2015 B2
9114231 Woehr et al. Aug 2015 B2
9114241 Stout et al. Aug 2015 B2
9114244 Yeh et al. Aug 2015 B2
9119950 Mansour et al. Sep 2015 B2
9126017 Albert et al. Sep 2015 B2
9138572 Zeytoonian et al. Sep 2015 B2
9144672 Mansour et al. Sep 2015 B2
9162029 Zollinger Oct 2015 B2
9162037 Belson et al. Oct 2015 B2
9198831 Rogers Dec 2015 B2
9199062 Liska et al. Dec 2015 B2
9199063 Baid Dec 2015 B2
9212772 Ho et al. Dec 2015 B2
9220871 Thörne et al. Dec 2015 B2
9227038 Woehr Jan 2016 B2
9233229 Emmert et al. Jan 2016 B2
9234616 Carrez et al. Jan 2016 B2
9238128 Yamaguchi et al. Jan 2016 B2
9238130 Mouri Jan 2016 B2
9259533 Weilbacher et al. Feb 2016 B2
9259537 Baney et al. Feb 2016 B2
9265882 Ito Feb 2016 B2
9271668 Crawford et al. Mar 2016 B2
9278180 Wong Mar 2016 B2
9278195 Erskine Mar 2016 B2
9278205 Quach et al. Mar 2016 B2
9289237 Woehr et al. Mar 2016 B2
9289588 Chen Mar 2016 B2
9308352 Teoh et al. Apr 2016 B2
9308353 Shaw et al. Apr 2016 B2
9308354 Farrell et al. Apr 2016 B2
9314604 Bonnal et al. Apr 2016 B2
9320469 Shaw et al. Apr 2016 B2
9320860 Grimm et al. Apr 2016 B2
9345641 Krause et al. May 2016 B2
9352127 Yeh et al. May 2016 B2
9370466 Garfield et al. Jun 2016 B2
9370641 Woehr et al. Jun 2016 B2
9370651 Zollinger et al. Jun 2016 B2
9375551 Harding Jun 2016 B2
9375552 Tremblay Jun 2016 B2
9381324 Fuchs et al. Jul 2016 B2
9381337 Carter et al. Jul 2016 B2
9393398 Truitt et al. Jul 2016 B2
9399116 Goral et al. Jul 2016 B2
9399119 Kuracina et al. Jul 2016 B2
9399120 Burkholz Jul 2016 B2
9408632 Erskine Aug 2016 B2
9409007 Yeh Aug 2016 B2
9415192 Kuracina et al. Aug 2016 B2
9421345 Woehr et al. Aug 2016 B2
9421352 Butts et al. Aug 2016 B2
9427549 Woehr et al. Aug 2016 B2
9433708 Eddy Sep 2016 B2
9433758 Farley et al. Sep 2016 B2
9522255 Knutsson Dec 2016 B2
9809355 Solomon et al. Nov 2017 B2
9827398 White et al. Nov 2017 B2
9962526 White et al. May 2018 B2
10086170 Chhikara et al. Oct 2018 B2
10159818 Farrell et al. Dec 2018 B2
20010041871 Brimhall Nov 2001 A1
20020045843 Barker et al. Apr 2002 A1
20020165497 Greene et al. Nov 2002 A1
20020169418 Menzi et al. Nov 2002 A1
20030032922 Moorehead Feb 2003 A1
20030073956 Hoffman et al. Apr 2003 A1
20030083620 Luther et al. May 2003 A1
20030083621 Shaw et al. May 2003 A1
20030120222 Vaillancourt Jun 2003 A1
20030181871 Wilkinson et al. Sep 2003 A1
20030195479 Kuracina et al. Oct 2003 A1
20030199827 Thorne Oct 2003 A1
20040010227 Riesenberger et al. Jan 2004 A1
20040106903 Shue et al. Jan 2004 A1
20040030294 Mahurkar Feb 2004 A1
20040064102 Yamada Apr 2004 A1
20040097888 Gutierrez May 2004 A1
20040102735 Moulton et al. May 2004 A1
20040111059 Howlett et al. Jun 2004 A1
20040116855 Popov et al. Jun 2004 A1
20040127856 Johnson Jul 2004 A1
20040143216 Douglas et al. Jul 2004 A1
20040181192 Cuppy Sep 2004 A1
20040206416 Paradis Oct 2004 A1
20040267210 Popovsky Dec 2004 A1
20050027263 Woehr et al. Feb 2005 A1
20050043709 Brimhall et al. Feb 2005 A1
20050045192 Fulton et al. Mar 2005 A1
20050059933 Johnson Mar 2005 A1
20050113755 Greene et al. May 2005 A1
20050131350 Shaw et al. Jun 2005 A1
20050192535 Takagi et al. Sep 2005 A1
20060015071 Fitzgerald Jan 2006 A1
20060015075 Blanco et al. Jan 2006 A1
20060030815 Csincsura et al. Feb 2006 A1
20060060892 Propp Mar 2006 A1
20060094983 Burbank et al. May 2006 A1
20060106335 Putter et al. May 2006 A1
20060116638 Woehr et al. Jun 2006 A1
20060155258 Rogers et al. Jul 2006 A1
20060189942 Chang et al. Aug 2006 A1
20060247577 Wright Nov 2006 A1
20060253076 Butts et al. Nov 2006 A1
20060264833 Moulton Nov 2006 A1
20060270994 Bierman Nov 2006 A1
20070016149 Hunn et al. Jan 2007 A1
20070038179 Bialecki et al. Feb 2007 A1
20070038182 Bialecki et al. Feb 2007 A1
20070038183 Bialecki et al. Feb 2007 A1
20070038185 Albert et al. Feb 2007 A1
20070038186 Sutton et al. Feb 2007 A1
20070038187 Albert et al. Feb 2007 A1
20070060892 Propp Mar 2007 A1
20070066958 Wright Mar 2007 A1
20070066960 Jones et al. Mar 2007 A1
20070073221 Bialecki et al. Mar 2007 A1
20070078400 Gesler, III Apr 2007 A1
20070079894 Krause et al. Apr 2007 A1
20070129689 Woehr et al. Jun 2007 A1
20070142785 Lundgaard et al. Jun 2007 A1
20070161950 Carlyon et al. Jul 2007 A1
20070173768 Bierman Jul 2007 A2
20070179446 Carrez et al. Aug 2007 A1
20070185454 Fangrow Aug 2007 A1
20070185455 Fangrow Aug 2007 A1
20070191776 Bialecki et al. Aug 2007 A1
20070191777 King Aug 2007 A1
20070244438 Perez Oct 2007 A1
20070250011 Lee Oct 2007 A1
20070250057 Nobis et al. Oct 2007 A1
20070255212 Smith et al. Nov 2007 A1
20070265572 Smith et al. Nov 2007 A1
20070270754 Soderholm et al. Nov 2007 A1
20070270758 Hanner et al. Nov 2007 A1
20080039796 Nakajima Feb 2008 A1
20080051726 Lee et al. Feb 2008 A1
20080097315 Miner et al. Apr 2008 A1
20080108944 Woehr et al. May 2008 A1
20080125717 Shue et al. May 2008 A1
20080132846 Shue et al. Jun 2008 A1
20080135443 Frojd et al. Jun 2008 A1
20080140004 Thorne et al. Jun 2008 A1
20080140011 Hager et al. Jun 2008 A1
20080147009 Nilsson et al. Jun 2008 A1
20080195033 Eagleson et al. Aug 2008 A1
20080200791 Simpson et al. Aug 2008 A1
20080215009 Shaw et al. Sep 2008 A1
20080228144 Liniger et al. Sep 2008 A1
20080262431 Anderson et al. Oct 2008 A1
20080287876 Shue et al. Nov 2008 A1
20080300543 Abriles et al. Dec 2008 A1
20080300574 Belson et al. Dec 2008 A1
20090012480 Moulton et al. Jan 2009 A1
20090036836 Nystrom et al. Feb 2009 A1
20090036914 Houser Feb 2009 A1
20090043260 Bierman Feb 2009 A1
20090069751 Curtis et al. Mar 2009 A1
20090076435 Melsheimer et al. Mar 2009 A1
20090082732 Hillman Mar 2009 A1
20090082733 Fujii Mar 2009 A1
20090124981 Evans May 2009 A1
20090131870 Fiser May 2009 A1
20090131872 Popov May 2009 A1
20090137958 Erskine May 2009 A1
20090137961 Bracken May 2009 A1
20090163861 Carlyon Jun 2009 A1
20090177167 Kuracina et al. Jul 2009 A1
20090221961 Tal et al. Sep 2009 A1
20090227896 Tan et al. Sep 2009 A1
20090299295 Rubinstein et al. Dec 2009 A1
20090306602 Elwell et al. Dec 2009 A1
20100004604 Stearns Jan 2010 A1
20100016804 Muskatello et al. Jan 2010 A1
20100036331 Sen Feb 2010 A1
20100094310 Warring et al. Apr 2010 A1
20100106135 Radmand Apr 2010 A1
20100114063 Recinella et al. May 2010 A1
20100137815 Kuracina et al. Jun 2010 A1
20100137833 Glynn Jun 2010 A1
20100168675 Cindrich et al. Jul 2010 A1
20100204648 Stout et al. Aug 2010 A1
20100210934 Belson Aug 2010 A1
20100222746 Burkholz Sep 2010 A1
20100234804 Hiejima et al. Sep 2010 A1
20100241088 Ranalletta et al. Sep 2010 A1
20100262038 Tan et al. Oct 2010 A1
20100262083 Grunhut et al. Oct 2010 A1
20100268156 Milacek et al. Oct 2010 A1
20100274199 Weston Oct 2010 A1
20100286615 Gyrn et al. Nov 2010 A1
20100286620 Edginton et al. Nov 2010 A1
20100286623 Liversidge Nov 2010 A1
20100292673 Korogi et al. Nov 2010 A1
20100305519 McKinnon et al. Dec 2010 A1
20100318063 Soll Dec 2010 A1
20110015573 Maan et al. Jan 2011 A1
20110021994 Anderson et al. Jan 2011 A1
20110040281 White et al. Feb 2011 A1
20110054404 Tanabe et al. Mar 2011 A1
20110060288 Carlyon et al. Mar 2011 A1
20110077592 Takemoto Mar 2011 A1
20110125096 Baid May 2011 A1
20110125097 Shaw et al. May 2011 A1
20110178427 Tan et al. Jul 2011 A1
20110178464 Rawls Jul 2011 A1
20110178478 Huet et al. Jul 2011 A1
20110196260 Melsheimer et al. Aug 2011 A1
20110208124 Rhad et al. Aug 2011 A1
20110213307 Kawai et al. Sep 2011 A1
20110224617 Miner Sep 2011 A1
20110306933 Djordjevic et al. Dec 2011 A1
20120010577 Liska et al. Jan 2012 A1
20120016312 Brown et al. Jan 2012 A1
20120022464 Zivkovic et al. Jan 2012 A1
20120191010 Cabot Jan 2012 A1
20120035552 Woehr Feb 2012 A1
20120041371 Tal et al. Feb 2012 A1
20120041377 Haak Feb 2012 A1
20120056746 Kaigler et al. Mar 2012 A1
20120065612 Stout et al. Mar 2012 A1
20120109077 Ryan May 2012 A1
20120123381 Krause et al. May 2012 A1
20120143151 Low et al. Jun 2012 A1
20120150117 Andino Jun 2012 A1
20120150121 Silverman et al. Jun 2012 A1
20120153201 Larose et al. Jun 2012 A1
20120184910 Woehr Jul 2012 A1
20120191071 Butts et al. Jul 2012 A1
20120197200 Belson Aug 2012 A1
20120197205 Peters Aug 2012 A1
20120220944 Charlez Aug 2012 A1
20120220955 Maseda et al. Aug 2012 A1
20120220956 Kuracina et al. Aug 2012 A1
20120226240 Bedford et al. Sep 2012 A1
20120259293 Bialecki et al. Oct 2012 A1
20120316536 Carrez et al. Dec 2012 A1
20120323181 Shaw et al. Dec 2012 A1
20120330248 Woehr Dec 2012 A1
20130030370 Walker et al. Jan 2013 A1
20130041313 Chung Feb 2013 A1
20130053781 Woehr et al. Feb 2013 A1
20130053815 Mucientes et al. Feb 2013 A1
20130060197 Woehr et al. Mar 2013 A1
20130060198 Woehr et al. Mar 2013 A1
20130060199 Baid Mar 2013 A1
20130060201 Popov Mar 2013 A1
20130060205 Mansour et al. Mar 2013 A1
20130066276 Ito et al. Mar 2013 A1
20130079730 Mosler et al. Mar 2013 A1
20130096504 Walker et al. Apr 2013 A1
20130110036 Fojtik May 2013 A1
20130116598 Howell et al. May 2013 A1
20130150784 Rodriguez Lelis et al. Jun 2013 A1
20130158506 White et al. Jun 2013 A1
20130178798 Pearson et al. Jul 2013 A1
20130178825 Helm, Jr. Jul 2013 A1
20130211325 Wang et al. Aug 2013 A1
20130226144 Milligan Aug 2013 A1
20130231630 Krause et al. Sep 2013 A1
20130261554 Baid Oct 2013 A1
20130296808 Triplett et al. Nov 2013 A1
20140012196 Zivkovic et al. Jan 2014 A1
20140012206 Shaw et al. Jan 2014 A1
20140025036 Bierman et al. Jan 2014 A1
20140039399 Burkholz Feb 2014 A1
20140052065 Woehr et al. Feb 2014 A1
20140058329 Walker et al. Feb 2014 A1
20140058357 Keyser et al. Feb 2014 A1
20140074032 Bornhoft Mar 2014 A1
20140081210 Bierman et al. Mar 2014 A1
20140100528 Finnestad et al. Apr 2014 A1
20140107619 Butts et al. Apr 2014 A1
20140135702 Woehr et al. May 2014 A1
20140135703 Yeh et al. May 2014 A1
20140163470 Baid Jun 2014 A1
20140163523 Constantineau et al. Jun 2014 A1
20140171876 Shaw et al. Jun 2014 A1
20140174578 Bonnal et al. Jun 2014 A1
20140180212 Baid Jun 2014 A1
20140180250 Belson Jun 2014 A1
20140188003 Belson Jul 2014 A1
20140221931 Kuracina et al. Aug 2014 A1
20140257202 Woehr Sep 2014 A1
20140261860 Heath et al. Sep 2014 A1
20140276453 Woehr Sep 2014 A1
20140276458 Mansour et al. Sep 2014 A1
20140276459 Yeh et al. Sep 2014 A1
20140276462 Vincent et al. Sep 2014 A1
20140276466 Yeh et al. Sep 2014 A1
20140296794 Li Oct 2014 A1
20140296829 White et al. Oct 2014 A1
20140303561 Li Oct 2014 A1
20140316350 Yamaguchi et al. Oct 2014 A1
20140323980 Cronenberg et al. Oct 2014 A1
20140336582 Tisci et al. Nov 2014 A1
20140336583 Morrissey et al. Nov 2014 A1
20140364809 Isaacson et al. Dec 2014 A1
20140371686 Sano et al. Dec 2014 A1
20150005718 Walker et al. Jan 2015 A1
20150038943 Warring et al. Feb 2015 A1
20150045746 Macy, Jr. et al. Feb 2015 A1
20150080801 Tanabe et al. Mar 2015 A1
20150148748 Shluzas et al. May 2015 A1
20150148749 Cohn May 2015 A1
20150148756 Lynn May 2015 A1
20150151083 White et al. Jun 2015 A1
20150157799 Chen et al. Jun 2015 A1
20150157800 Chen et al. Jun 2015 A1
20150157848 Wu et al. Jun 2015 A1
20150165132 Perot et al. Jun 2015 A1
20150174339 Bokelman et al. Jun 2015 A1
20150174374 Woehr Jun 2015 A1
20150190168 Bierman et al. Jul 2015 A1
20150190627 Ueda et al. Jul 2015 A1
20150196737 Baid Jul 2015 A1
20150196749 Ziv et al. Jul 2015 A1
20150196750 Ueda et al. Jul 2015 A1
20150202424 Harton Jul 2015 A1
20150209508 Constantineu et al. Jul 2015 A1
20150224267 Farrell et al. Aug 2015 A1
20150258325 Panian et al. Sep 2015 A1
20150265829 Truitt et al. Sep 2015 A1
20150290431 Hall et al. Oct 2015 A1
20150297817 Guala Oct 2015 A1
20150297880 Ogawa et al. Oct 2015 A1
20150313523 Chelak et al. Nov 2015 A1
20150328438 Baid Nov 2015 A1
20150352331 Helm, Jr. Dec 2015 A1
20150352333 Arellano Cabrera et al. Dec 2015 A1
20160000364 Mendels et al. Jan 2016 A1
20160001057 Lopez et al. Jan 2016 A1
20160015943 Belson et al. Jan 2016 A1
20160015945 Warring et al. Jan 2016 A1
20160015958 Ueda et al. Jan 2016 A1
20160015961 Mansour et al. Jan 2016 A1
20160022963 Belson Jan 2016 A1
20160022977 Ueda et al. Jan 2016 A1
20160022978 Ueda Jan 2016 A1
20160030730 Mosler et al. Feb 2016 A1
20160038730 Zollinger Feb 2016 A1
20160088995 Ueda et al. Mar 2016 A1
20160114136 Woeher Apr 2016 A1
20160114137 Woehr et al. Apr 2016 A1
20160114147 Siopes et al. Apr 2016 A1
20160121082 Emmert et al. May 2016 A1
20160129180 Roman et al. May 2016 A1
20160135841 Albert et al. May 2016 A1
20160136051 Lavi May 2016 A1
20160158498 White et al. Jun 2016 A1
20160158499 Helm Jun 2016 A1
20160158524 Quach et al. Jun 2016 A1
20160183976 Bertoli et al. Jun 2016 A1
20160199575 Belley et al. Jul 2016 A1
20160206813 Abe et al. Jul 2016 A1
20160206858 Ishida Jul 2016 A1
20160220270 Tamura et al. Aug 2016 A1
20160235944 Ma Aug 2016 A1
20160235949 Baid Aug 2016 A1
20160235961 Maffei Aug 2016 A1
20160256667 Ribelin et al. Sep 2016 A1
20160263353 Kuracina et al. Sep 2016 A1
20160271370 Keyser et al. Sep 2016 A1
20160296724 Goral et al. Oct 2016 A1
20160325078 Burkholz Nov 2016 A1
20170000983 Woehr Jan 2017 A1
20170182293 Chhikara Jun 2017 A1
20170239443 Abitabilo et al. Aug 2017 A1
20180154119 White Jun 2018 A1
20190091448 Chhikara Mar 2019 A1
20190282784 Farrell Sep 2019 A1
Foreign Referenced Citations (26)
Number Date Country
101466431 Jun 2009 CN
0 576 302 Dec 1993 EP
0 821 980 Apr 2003 EP
1 323 442 Jul 2003 EP
56-130161 Oct 1981 JP
03-501818 Apr 1991 JP
H06-78999 Mar 1994 JP
10-015075 Jan 1998 JP
2901915 Jun 1999 JP
2005-261931 Sep 2005 JP
2008-528225 Jul 2008 JP
4211858 Jan 2009 JP
WO 199001351 Feb 1990 WO
WO 1997015342 May 1997 WO
WO 2006082350 Aug 2006 WO
WO 2006090148 Aug 2006 WO
WO 2007008511 Jan 2007 WO
WO 2007052656 May 2007 WO
WO 2007143555 Dec 2007 WO
WO 2008042285 Apr 2008 WO
WO 2009032008 Mar 2009 WO
WO 2009092076 Jul 2009 WO
WO 2011146764 Nov 2011 WO
WO 2011146769 Nov 2011 WO
WO 2015119940 Aug 2015 WO
WO 2018009653 Jan 2018 WO
Non-Patent Literature Citations (3)
Entry
European Supplementary Search Report, re EP Application No. EP 10 80 8800.6, dated May 9, 2014. (TMED.009EP).
International Search Report and Written Opinion, re CPT Application No. PCT/US2010/045426, dated Apr. 20, 2011. (TMED.009WO).
BD Nexiva Closed IV Catheter System, http://www.bd.com/infusion/products/ivcatheters/nexiva/index.asp, downloaded Sep. 6, 2013 in 19 pages.
Related Publications (1)
Number Date Country
20190076625 A1 Mar 2019 US
Provisional Applications (1)
Number Date Country
61233859 Aug 2009 US
Continuations (5)
Number Date Country
Parent 15427714 Feb 2017 US
Child 15951509 US
Parent 14602735 Jan 2015 US
Child 15427714 US
Parent 13930797 Jun 2013 US
Child 14602735 US
Parent 13665162 Oct 2012 US
Child 13930797 US
Parent 12855013 Aug 2010 US
Child 13665162 US